Evidence map›Paper›PMID 40079128›Full record

ArticleInternational health2025

Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa.

Deborah Ekusai-Sebatta, Ritah Shanice Namugenyi, Eva Laker, Erisa Mwaka, Rachel King, David S Lawrence, Janet Seeley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Deborah Ekusai-SebattaInfectious Diseases Institute, Research Department, College of Health Sciences, Makerere University, P.O Box 22418 Kampala, Uganda.ORCID 0000-0001-8113-6185
Ritah Shanice NamugenyiMakerere University, Department of Anatomy, College of Health Sciences, School of Biomedical Sciences, P.O Box 7072, Kampala, Uganda.
Eva LakerInfectious Diseases Institute, Research Department, College of Health Sciences, Makerere University, P.O Box 22418 Kampala, Uganda.
Erisa MwakaMakerere University, Department of Anatomy, College of Health Sciences, School of Biomedical Sciences, P.O Box 7072, Kampala, Uganda.
Rachel KingDepartment of Epidemiology and Biostatistics & Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA.
David S LawrenceDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, P.O Box WC1E 7HT, London, UK.
Janet SeeleyDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, P.O Box WC1E 7HT, London, UK.ORCID 0000-0002-0583-5272

Funding

National Institute for Health and Care Research NIHR134342NIH HHS BO-0423NIH HHS BO-1122NIH HHS P30A1027763
6 · The paper itself

Abstract

backgroundThis article discusses the ethical issues surrounding the integration of long-acting injectable antiretroviral therapy (LA-ART) in the programmatic management of human immunodeficiency virus (HIV). As the medical landscape evolves, implementing LA-ART introduces many ethical issues that should be considered for the success of scale-up in diverse settings.

methodsThis article examines key issues such as bioethical concerns around the rollout of LA-ART, including regulatory requirements, a person's autonomy, informed consent, privacy and confidentiality; the societal implications of providing LA-ART, including the impact on stigma and discrimination; ethics around who receives LA-ART, financial accessibility, equitable access, inclusive decision-making and cultural sensitivity; and the ethics of providing an expensive intervention, including cost-effectiveness, supply chain sustainability and resource allocation. By critically analysing the ethical issues, we aim to guide policymakers and identify areas for further research.

conclusionOur overarching aim is to ensure that the rights of people living with HIV are protected as implementors plan for the rollout of LA-ART with a focus on eastern and southern Africa. The utilization of LA-ART in resource-limited settings poses significant ethical challenges, necessitating careful consideration of autonomy, access and equity, stigma, discrimination, sustainability and treatment adherence.

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsHIV InfectionsAfrica South of the SaharaConfidentialityHealth Services AccessibilityHumansInformed ConsentInjectionsPersonal AutonomySocial StigmaAnti-HIV AgentsAnti-Retroviral AgentscabotegravirethicsHIVinjectable antiretroviral therapyrilpivirinesub-Saharan Africa

Identifiers

PMID40079128
PMCPMC12406793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.